AR056319A1 - Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios - Google Patents

Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios

Info

Publication number
AR056319A1
AR056319A1 ARP060101569A ARP060101569A AR056319A1 AR 056319 A1 AR056319 A1 AR 056319A1 AR P060101569 A ARP060101569 A AR P060101569A AR P060101569 A ARP060101569 A AR P060101569A AR 056319 A1 AR056319 A1 AR 056319A1
Authority
AR
Argentina
Prior art keywords
hydroalkyl
group
optionally substituted
lower alkyl
hydrogen
Prior art date
Application number
ARP060101569A
Other languages
English (en)
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of AR056319A1 publication Critical patent/AR056319A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Estos compuestos son utiles como inhibidores de la p38-quinasa para el tratamiento o prevencion y tratamiento de enfermedades tales como enfermedades inflamatorias, enfermedades autoinmunes, trastornos oseos destructivos, trastornos proliferativos, trastornos angiogénicos, enfermedades infecciosas, enfermedades neurodegenerativas y enfermedades virales. Son también objetos de la presente una composicion farmacéutica en base al compuesto y compuestos intermediarios de síntesis. Reivindicacion 1: Un método para inhibir la p38-quinasa caracterizado porque comprende contactar p38 con un compuesto de formula (1), o una de sus sales, ésteres, tautomeros o profármacos, donde: L, M, T, X y Y se seleccionan, cada uno en forma independiente, del grupo que consiste en N, C, O y S; Q, U, V y W se seleccionan, cada uno en forma independiente, del grupo que consiste en N y C; Z se selecciona del grupo que consiste en N, C(O), C, O y S; R1 se selecciona del grupo que consiste en alcoxi, alquilo inferior, alquilacilo inferior, alquiloxi inferior, alquiléter inferior, amida, amino, aminoalquilo, halo, hidrogeno, hidroxi y ninguno, cualquiera de los cuales puede estar opcionalmente sustituido; R2 se selecciona del grupo que consiste en - C(O)R9, -C(S)(NR10R11), -C[N(OR12)]R13, -C(NR14)(NR10R11) y -S(O)nR15; n es O, 1 o 2; R3 se selecciona del grupo que consiste en alcoxi, alquilo inferior, alquiléter inferior, amino, aminoalquilo inferior, halo, haloalquilo, hidrogeno, hidroxi y ninguno, cada uno de los cuales puede estar opcionalmente sustituido; R4 se selecciona del grupo que consiste en alquilo inferior, halo, haloalquilo, hidrogeno y ninguno, cada uno de los cuales puede estar opcionalmente sustituido; R5 y R6 se seleccionan cada uno en forma independiente del grupo que consiste en acilo, alcanoílo, alcoxi, alcoxiarilo, alquilo inferior, alquileno, amido, amino, aminoalquilo, arilo, aralquilo, carboxi, ciano, cicloalquilo, cicloalquilalquilo, cicloalquiloxi, éster, guanidino, halo, haloalcoxi, haloalquilo, heteroaralquilo, heterocicloalquilo, heterocicloalquilalquilo, hidrogeno, hidroxi, imino, iminohidroxi, nitro, ninguno, O-carbamoilo, N-carbamoilo, S-sulfonamido, tio y ureido, cualquiera de los cuales puede estar opcionalmente sustituido, o R5 y R6 pueden combinarse y formar un heteroarilo o heterocicloalquilo, cada uno de los cuales puede estar sustituido opcionalmente; R7 se selecciona del grupo que consiste en alquilacilo inferior, alquilo inferior, alquiléter inferior, halo, hidrogeno, hidroxi, hidroxialquilo y ninguno, cada uno de los cuales puede estar opcionalmente sustituido; R8 se selecciona del grupo que consiste en arilo y heteroarilo, cada uno de los cuales puede estar sustituido opcionalmente; R9 se selecciona del grupo que consiste en NR16R17, OR18, SR19, alquilo inferior, alquenilo inferior, alquinilo, amino, aminoalquilo inferior, aralquilo, arilo, arilamino, arilcarbonilo, ariltio, arilsulfonilo, carbonilalquilo, carboxi, cicloalquilo, cicloalquilalquilo, cicloalquenilo, cicloalquilamino, haloalquilo, heteroaralquilo, heterocicloalquilo, heterocicloalquilalquilo, hidrogeno, hidroxialquilo, O-carbamoilo y N-carbamoilo, cualquiera de los cuales puede estar opcionalmente sustituido; R10, R11, R14, R16 y R17 cada uno se selecciona en forma independiente del grupo que consiste en acilo, alquenilo inferior, alquinilo, alcoxi inferior, alcoxialquilo inferior, alquilo inferior, alquiltio, amino, aminoalquilo, aminocarbonilo, aralquilo, arilamino, arilcarbonilo, arilsulfonilo, cicloalquilo, cicloalquilalquilo, carboxi, cicloalquenilo, cicloalquilo, haloalquilo, hidroxialquilo, heteroarilo, heteroaralquilo, heterocicloalquilo, heterocicloalquilalquilo e hidrogeno, cualquiera de los cuales puede estar opcionalmente sustituido, o cada par de R10 y R11 o R16 y R17 se pueden combinar y formar heterocicloalquilo, que puede estar opcionalmente sustituido; R12 y R13 se seleccionan, cada uno, en forma independiente del grupo que consiste en alquenilo inferior, alquilo inferior, alquinilo inferior, aralquilo, arilo, cicloalquilo, cicloalquilalquilo, haloalquilo, heteroaralquilo, heterocicloalquilo, heterocicloalquilalquilo e hidrogeno, cualquiera de los cuales puede estar opcionalmente sustituido; R15 se selecciona del grupo que consiste en alquenilo inferior, alcoxi inferior, alcoxialquilo inferior, alquilo inferior, alquilamino inferior, alquinilo, amino, aminocarbonilo, aralquilo, arilaminocarbonilo, arilcarbonilo, arilsulfonilo, cicloalquilo, carbonilalquilo, cicloalquenilo, cicloalquilo, haloalquilo, hidroxilo, hidroxialquilo, heteroaralquilo, heterocicloalquilo, hidrogeno, tio y tioalquilo inferior, cualquiera de los cuales puede estar opcionalmente sustituido; y R18 y R19 se seleccionan, cada uno, en forma independiente del grupo que consiste en alquenilo inferior, alquilo inferior, alquinilo inferior, aralquilo, cicloalquilo, haloalquilo, heteroaralquilo, heterocicloalquilo e hidrogeno, cualquiera de los cuales puede estar opcionalmente sustituido.
ARP060101569A 2005-04-22 2006-04-20 Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios AR056319A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67404705P 2005-04-22 2005-04-22
US77659406P 2006-02-24 2006-02-24

Publications (1)

Publication Number Publication Date
AR056319A1 true AR056319A1 (es) 2007-10-03

Family

ID=36725835

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101569A AR056319A1 (es) 2005-04-22 2006-04-20 Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios

Country Status (6)

Country Link
US (1) US20060252807A1 (es)
EP (1) EP1871770A1 (es)
AR (1) AR056319A1 (es)
CA (1) CA2605603A1 (es)
TW (1) TW200720272A (es)
WO (1) WO2006116355A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013400A (es) 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2008656A1 (en) 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
GB2451629A (en) * 2007-08-06 2009-02-11 Univ Sheffield 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones
DK2206707T3 (da) 2007-10-24 2014-08-11 Astellas Pharma Inc Azolcarboxamidforbindelse eller salt deraf
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
PE20120003A1 (es) 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
EP2404902A1 (en) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
US20120220603A1 (en) * 2009-09-04 2012-08-30 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
CN103038229B (zh) * 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2012020738A1 (ja) * 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
MX352307B (es) * 2011-02-01 2017-11-17 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas.
JP6054869B2 (ja) * 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
WO2014134306A1 (en) 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
CN104230912B (zh) * 2014-09-03 2017-06-06 中国科学院福建物质结构研究所 喹啉衍生物、其制备方法及其用途
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
EP3365339A1 (en) * 2015-10-23 2018-08-29 Vifor (International) AG Novel ferroportin inhibitors
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
CN113069451B (zh) * 2021-04-02 2022-08-09 苏州大学 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816120A1 (de) * 1988-05-11 1989-11-23 Bayer Ag Verfahren zur herstellung von unsymmetrischen biarylverbindungen
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
EP0930305B1 (en) * 1996-09-30 2003-05-14 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
RU2249591C2 (ru) * 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
WO2002051442A1 (fr) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Co-prescriptions
GB0102687D0 (en) * 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
MXPA03009846A (es) * 2001-04-27 2004-05-05 Vertex Pharma Derivados de triazol inhibidores de cinasa y usos de los mismos.
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
CA2496633A1 (en) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
US7119208B2 (en) * 2003-12-03 2006-10-10 Virginia Commonwealth University Anti-sickling agents

Also Published As

Publication number Publication date
WO2006116355A1 (en) 2006-11-02
EP1871770A1 (en) 2008-01-02
CA2605603A1 (en) 2006-11-02
TW200720272A (en) 2007-06-01
US20060252807A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
AR056319A1 (es) Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
AR061032A1 (es) Alaninas sustituidas por heteroaroilo y preparacion de agentes herbicidas
AR057979A1 (es) PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
AR062074A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20240221A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
HRP20171999T1 (hr) Novi derivati aminopirimidina
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
AR077818A1 (es) Composiciones pesticidas
AR065276A1 (es) Herbicidas de n-oxidos de piridina sustituidos
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
AR082153A1 (es) N-sulfonilbenzamidas utiles como inhibidor del canal de sodio
TW200602056A (en) Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
ES2601518T3 (es) Composiciones plaguicidas
BRPI0720858B8 (pt) pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
PE20050354A1 (es) Aminas ciclicas de bace-1 que poseen un sustituyente heterociclico
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
AR067897A1 (es) Compuestos para el tratamiento de hepatitis c
ECSP099639A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasa
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.

Legal Events

Date Code Title Description
FB Suspension of granting procedure